Skip to main content

Table 1 Treatment and imaging for each group

From: Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies

Group Number of mice Treatment Imaging
177Lu-TATE 4 50 MBq 177Lu-TATE i.v. 6 × MRI, 1 × SPECT/CT
TMZ 7 TMZ 50 mg/kg p.o. for 14 days 7 × MRI, 7 × SPECT/CT
Control 3 Saline 3 × MRI
  1. 177 Lu-TATE lutetium-177-labelled octreotate, TMZ temozolomide